-0.71%
8.87%
-7.90%
-11.56%
1.16%
80.37%
93.09%
AI Spotlight on VRTX
Company Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial.
The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally.It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc.Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Market Data
| Last Price | 438.4 |
| Change Percentage | -0.71% |
| Open | 443.56 |
| Previous Close | 441.52 |
| Market Cap ( Millions) | 112901 |
| Volume | 1047967 |
| Year High | 519.88 |
| Year Low | 377.85 |
| M A 50 | 438.71 |
| M A 200 | 458.47 |
Financial Ratios
| FCF Yield | -1.03% |
| Dividend Yield | 0.00% |
| ROE | -2.88% |
| Debt / Equity | 10.89% |
| Net Debt / EBIDTA | -683.08% |
| Price To Book | 7.24 |
| Price Earnings Ratio | -235.74 |
| Price To FCF | -97.01 |
| Price To sales | 10.64 |
| EV / EBITDA | 211.25 |
News
- 00:55 - FDA Approves Non-Opioid Painkiller With No Addiction Risk
- 00:04 - Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid Painkiller
- Jan -30 - Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
- Jan -30 - US FDA approves Vertex's non-opioid painkiller
- Jan -30 - FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
- Jan -30 - Investors who Lost Money on Vertex Pharmaceuticals Incorporated Should Contact Levi & Korsinsky About an Ongoing Investigation - VRTX
- Jan -29 - VRTX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Vertex Pharmaceuticals Incorporated
- Jan -29 - Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
- Jan -28 - Vertex Pharmaceuticals Incorporated (VRTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
- Jan -27 - Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
- Jan -27 - VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation
- Jan -26 - Is Vertex Pharmaceuticals Stock a Buy in 2025?
- Jan -25 - Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
- Jan -24 - VRTX STOCK ALERT: Levi & Korsinsky Notifies Vertex Pharmaceuticals Incorporated Investors of an Ongoing Investigation
- Jan -24 - 2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
- Jan -23 - Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
- Jan -23 - Investors who lost money on Vertex Pharmaceuticals Incorporated should contact Levi & Korsinsky about an ongoing investigation - VRTX
- Jan -23 - Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts
- Jan -22 - Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research
- Jan -22 - VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investment
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceutical
Expected Growth : 8.0 %
What the company do ?
Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes medicines for serious diseases, including cystic fibrosis, sickle cell disease, and alpha-1 antitrypsin deficiency.
Why we expect these perspectives ?
Vertex Pharmaceuticals' 8.0% growth is driven by strong sales of cystic fibrosis treatments, including Trikafta and Symdeko, as well as increasing adoption of its pipeline products, such as VX-147 for APOL1-mediated kidney disease. Additionally, the company's expanding presence in international markets and strategic collaborations contribute to its growth momentum.
Vertex Pharmaceuticals Incorporated Products
| Product Range | What is it ? |
|---|---|
| TRIKAFTA | A prescription medicine used for the treatment of cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| SYMDEKO | A prescription medicine used for the treatment of cystic fibrosis in patients aged 12 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| ORKAMBI | A prescription medicine used for the treatment of cystic fibrosis in patients aged 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| KALYDECO | A prescription medicine used for the treatment of cystic fibrosis in patients aged 4 months and older who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. |
| INCIVEK | A prescription medicine used for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection in adults with compensated liver disease, including cirrhosis. |
Vertex Pharmaceuticals Incorporated's Porter Forces
Threat Of Substitutes
Vertex Pharmaceuticals Incorporated has a moderate threat of substitutes due to the presence of alternative treatments for cystic fibrosis and other diseases. However, the company's strong pipeline and innovative products reduce the threat of substitutes.
Bargaining Power Of Customers
Vertex Pharmaceuticals Incorporated has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for its products.
Bargaining Power Of Suppliers
Vertex Pharmaceuticals Incorporated has a low bargaining power of suppliers due to the company's strong relationships with its suppliers and the lack of dependence on a single supplier.
Threat Of New Entrants
Vertex Pharmaceuticals Incorporated has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including the need for significant research and development investments and regulatory approvals.
Intensity Of Rivalry
Vertex Pharmaceuticals Incorporated operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company must continuously innovate and invest in research and development to maintain its market position.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 4.40% |
| Debt Cost | 5.87% |
| Equity Weight | 95.60% |
| Equity Cost | 5.87% |
| WACC | 5.87% |
| Leverage | 4.60% |
Vertex Pharmaceuticals Incorporated : Quality Control
Vertex Pharmaceuticals Incorporated passed 8 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INVA | Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol … |
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
| MCK | McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment … |
| MRNA | Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
AbbVie
A-Score
1-Year Total Return ->
🥈
Innoviva
A-Score
1-Year Total Return ->
🥉
Vertex Pharmaceuticals
A-Score
1-Year Total Return ->
4
McKesson
A-Score
1-Year Total Return ->
5
Regeneron Pharmaceuticals
A-Score
1-Year Total Return ->
6
